DURAMETRIX LLC

Medtech · Private

Imaging-based system for detecting toxicity-induced tissue injury in vivo during drug development

Grants
$2.2M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage$257,175
Federal grantDepartment of Health and Human Services · Phase II · Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage$1,011,661
Federal grantDepartment of Health and Human Services · Phase II · Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage$946,480
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
207021MedTech LLC——
2071VIZMA LIFE SCIENCES INC——
2072Double Helix Optics Inc——
2073DURAMETRIX LLC——
2074ClaimDetect LLC——
2075NUPROBE USA, INC.——
2076STETH X MICROSYSTEMS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.